IFNA2 and autoimmune polyendocrine syndrome type 1: Ninety-five percent of APS-1 patients display autoantibodies against IFN-ω and IFN-α [59], while interleukin-17 (IL-17) family cytokines, especially IL-22, are targeted in around 90 % of all patients [60], making these excellent screening tools to identify APS-1 patients.